<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455910</url>
  </required_header>
  <id_info>
    <org_study_id>020895</org_study_id>
    <secondary_id>CCPPRB Cochin 2402-1-1928</secondary_id>
    <nct_id>NCT00455910</nct_id>
  </id_info>
  <brief_title>Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200</brief_title>
  <official_title>Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GFM previously conducted a dose-escalating phase II trial of thalidomide in MDS with a
      minimum dose of 200mg/d and a maximum dose 800mg/d. Responses were evaluated according to IWG
      criteria at week 16 and thalidomide continued up to week 56 in responders. 82% patients
      received at least 8 weeks of treatment and were evaluable. 59% had hematological improvement,
      mainly on the erythroid lineage (Increase of Hemoglobin). Most responses were observed at low
      doses and between 4 and 8 weeks.

      The objectives of this trial (Thal-SMD-20) are to evaluate the efficacy and tolerance of
      lower doses thalidomide in low risk MDS patients with transfusion-dependant anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide:

      First part of the trial: 82 patients at 200mg/day given at bedtime x 12 weeks, decreased to
      100mg/day if grade 1 or 2 side. Stopped temporally for 1 week if grade 3 or 4 side effects.
      Then reintroduced at the same dose. If side effects again, definitively stopped.

      Responses evaluated at 12 weeks according to IWG criteria for the erythroid lineage

      At week 12:

        -  If no Hematological improvement (HI): increased to 300mg/day for 8 weeks and then
           eventually to 400mg/day for 8 weeks more, if no HI.

        -  If Hematological improvement (HI): continued at the same dose.

      Second part of the trial: 30 patients treated at 50mg/day x 12 weeks. Responses evaluated at
      12 weeks according to IWG criteria for the erythroid lineage

      At week 12:

        -  If no Hematological improvement (HI): increased to 100mg/day for 8 weeks and then
           eventually to 200mg/day for 8 weeks more, if no HI.

        -  If Hematological improvement (HI): continued at the same dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy evaluated at week 12 according to the IWG criterias</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>112</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥18 years, with IPSS Low or Int-1 MDS

          -  Transfusion dependant anemia above 2 packed red blood cells (PRBC)/month

          -  ECOG index = 0, 1, 2

          -  No peripheral neurological disease

        Exclusion Criteria:

          -  MDS patients with IPSS Int-2 or High

          -  Patients with less than 2 packed red blood cells (PRBC)/month

          -  Patients with previous history of venous thrombosis

          -  Patient treated with EPO +/- G-CSF in the 2 months before inclusion in the protocol

          -  Patient having received intensive chemotherapy in the 3 months before inclusion in the
             protocol

          -  Patient having received Thalidomide in a previous protocol

          -  Patient presenting an iron, B12 vitamin or folic acid uncorrected deficiency

          -  Patient with peripheral neurological disease

          -  Patient not being able to subject itself to a regular clinical and biological
             follow-up

          -  Pregnant patient or patient in a period of lactation

          -  Patient refusing to take a contraceptive treatment through out all the study

          -  Patient receiving drugs able to interfere with the mechanism of action of Thalidomide

          -  Patient refusing to sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Bouscary, MD, Ph-D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myelodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49 033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29 609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38 043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital C. Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44 093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hopital de l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06 202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75 004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75 012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66 046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henry Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76 038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy-Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gfmgroup.org</url>
    <description>website of French Group of Myelodysplasia</description>
  </link>
  <reference>
    <citation>Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-Rauzy O, Quarre MC, Vassilief D, Varet B, Aouba A, Gardembas M, Giraudier S, Guerci A, Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P, Dreyfus F; Groupe FranÃ§ais des MyÃ©lodysplasies (GFM). A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe FranÃ§ais des MyÃ©lodysplasies. Br J Haematol. 2005 Dec;131(5):609-18.</citation>
    <PMID>16351636</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 3, 2007</last_update_submitted>
  <last_update_submitted_qc>April 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2007</last_update_posted>
  <keyword>Low risk myelodysplastic syndromes</keyword>
  <keyword>MDS</keyword>
  <keyword>Bone marrow diseases</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Cytopenias</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

